aetherAI (7803) reported revenue of NT$5.8 million for Oct 2026, -88.1% year on year and -34.6% from the previous month. Revenue for Jan–Oct 2026 was NT$55 million (-70.7% year on year).
In Oct 2026, it ranked No. 137 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$5.8 million | -88.1% | -34.6% |
| Sep 2026 | NT$8.8 million | -63.6% | +24.9% |
| Aug 2026 | NT$7 million | -89.0% | +418.2% |
| Jul 2026 | NT$1.4 million | -40.0% | -57.3% |
| Jun 2026 | NT$3.2 million | -84.9% | -80.8% |
| May 2026 | NT$16.6 million | +1,440.6% | +1,048.5% |
| Apr 2026 | NT$1.4 million | -90.6% | -82.9% |
| Mar 2026 | NT$8.5 million | -24.2% | +1,056.5% |
| Feb 2026 | NT$731,000 | +240.0% | -54.7% |
| Jan 2026 | NT$1.6 million | +564.6% | -69.2% |
| Dec 2025 | NT$5.2 million | -89.1% | +493.7% |
| Nov 2025 | NT$884,000 | -53.7% | -98.2% |
| Oct 2025 | NT$48.2 million | +4,185.0% | +99.8% |
| Sep 2025 | NT$24.1 million | +3,558.3% | -62.2% |
| Aug 2025 | NT$63.9 million | +1,328.1% | +2,720.2% |
| Jul 2025 | NT$2.3 million | +79.8% | -89.3% |
| Jun 2025 | NT$21.1 million | +1,535.0% | +1,856.5% |
| May 2025 | NT$1.1 million | -28.7% | -93.0% |
| Apr 2025 | NT$15.4 million | +32.6% | +38.1% |
| Mar 2025 | NT$11.1 million | -19.7% | +5,084.2% |
| Feb 2025 | NT$215,000 | -97.0% | -11.5% |
| Jan 2025 | NT$243,000 | -96.9% | -99.5% |
| Dec 2024 | NT$48.2 million | +1,346.4% | +2,423.2% |
| Nov 2024 | NT$1.9 million | -91.4% | +69.6% |
| Oct 2024 | NT$1.1 million | — | +70.6% |
Jan–Oct 2026 cumulative: NT$55 million (-70.7% YoY)
Other Biotech & Medical companies
Compare with peers: aetherAI vs PEC / aetherAI vs Lotus Pharm / aetherAI vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
Company remark (original Chinese)
去年同期有專案驗收完成,故認列收入。
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16